Efficacy and Safety of Ponatinib as a Second‑Line Treatment for Chronic‑Phase Chronic Myeloid Leukemia: Retrospective Study at Two Japanese CentersYoshimi Ishii, Hideaki Nakajima, Katsumichi Fujimaki et al.|Indian Journal of Hematology and Blood Transfusion|2026Cited by 0